Gilead Sciences Inc

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: GILD-1 Category:

Description

Gilead started 2022 on a positive note with the HIV business, Trodelvy, Veklury, and cell therapy driving growth. The company’s revenue of these products was up 3% in comparison to the previous year. Primarily driven by Biktarvy, the HIV business grew at 2% year over year. The growing oncology portfolio of the company performed quite well with a doubling of Trodelvy revenue, and cell therapy has delivered another robust quarter of growth. The portfolio of marketed cancer therapy was expanded and for second-line refractory and relapsed LBCL FDA has approved Yescarta. Kite, a Gilead Company, recently announced that the Food and Drug Administration of the U.S has approved the commercial production in the new CAR T-cell therapy manufacturing facility in Fedrick, Maryland. Potential pathways are being explored for approval to bring Trodelvy to the patients who are at later stages. Another good news for the company was the U.S. FDA lifting the hold on Capella for HIV. Signs of recovery are viewed in the treatment market of HIV even though diagnosis and screening rates are below pre-pandemic levels. We provide the company a ‘Hold’ rating with a revision of the target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!

Menu